Pacira Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PCRX)

$40.30 0.00 (0.00 %)
(As of 01/18/2018 10:49 AM ET)
Previous Close$40.30
Today's Range$39.80 - $40.90
52-Week Range$29.81 - $58.95
Volume514,200 shs
Average Volume906,500 shs
Market Capitalization$1.63 billion
P/E Ratio-30.76
Dividend YieldN/A
Beta2.2

About Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:PCRX
CUSIP69512710
Phone+1-973-2543560

Debt

Debt-to-Equity Ratio1.03%
Current Ratio6.99%
Quick Ratio6.24%

Price-To-Earnings

Trailing P/E Ratio-30.763358778626
Forward P/E Ratio-47.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$276.37 million
Price / Sales5.92
Cash Flow$0.31 per share
Price / Cash132.08
Book Value$5.85 per share
Price / Book6.89

Profitability

Trailing EPS($1.31)
Net Income$-37,940,000.00
Net Margins-18.25%
Return on Equity-13.77%
Return on Assets-6.34%

Miscellaneous

Employees503
Outstanding Shares40,570,000

Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions

What is Pacira Pharmaceuticals' stock symbol?

Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."

How were Pacira Pharmaceuticals' earnings last quarter?

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) announced its earnings results on Wednesday, November, 8th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.15. The firm had revenue of $67.30 million for the quarter, compared to the consensus estimate of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. The business's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the company posted $0.20 EPS. View Pacira Pharmaceuticals' Earnings History.

When will Pacira Pharmaceuticals make its next earnings announcement?

Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Pacira Pharmaceuticals.

Where is Pacira Pharmaceuticals' stock going? Where will Pacira Pharmaceuticals' stock price be in 2018?

18 equities research analysts have issued 1-year target prices for Pacira Pharmaceuticals' shares. Their predictions range from $27.00 to $80.00. On average, they anticipate Pacira Pharmaceuticals' stock price to reach $49.47 in the next year. View Analyst Ratings for Pacira Pharmaceuticals.

What are Wall Street analysts saying about Pacira Pharmaceuticals stock?

Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product. The company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. The company discontinued DepoCyt(e) in June 2017 due to persistent technical issues and lower collaborative licensing and milestone revenues. However, during the third quarter of 2017, the FDA accepted the resubmission of Pacira's supplemental new drug application (sNDA) seeking expansion of Exparel label to include administration via nerve block for prolonged regional analgesia and set an action date of Apr 6, 2018. Additionally, Pacira remains optimistic of its partnership with J&J to market and promote the use of Exparel, with their sales and medical education teams. Loss estimates have narrowed ahead of the Q4 earnings." (1/9/2018)
  • 2. Canaccord Genuity analysts commented, "We’re looking for more than two months of data showing solid growth before we become positive on the potential for a meaningful inflection in Exparel use trends, especially with a noisy October that may have benefited from hurricane-related deferred procedures that negatively impacted September volumes. We remain HOLD rated on PCRX shares." (12/29/2017)
  • 3. Cowen Inc analysts commented, "Nerve block data for Exparel is anticipated within the next month, and our consultants." (7/14/2017)
  • 4. Mizuho analysts commented, "We continue to like PCRX for the 2017 potential catalyst flow (ahead of the nerve block data), growth opportunities from increased DePuy Synthes (DPS) orthopedic promotion, and a reasonable takeout thesis. We updated our share count and interest expense following the recent convertible debt refinancing, and included the latest Feb data from Symphony. While we are comfortable with the growth rates we estimate for the 20 mL vial, we need to monitor our expectations for the smaller 10 mL vial that launched this year and is not yet reported by Symphony. Our estimates came down slightly due to lowered expectations on this 10 mL vial and we lower our PT to $54 from $59 due to additional share count dilution and increase in net debt." (3/23/2017)

Who are some of Pacira Pharmaceuticals' key competitors?

Who are Pacira Pharmaceuticals' key executives?

Pacira Pharmaceuticals' management team includes the folowing people:

  • David M. Stack, Chairman of the Board, Chief Executive Officer (Age 66)
  • Charles A. Reinhart III, Chief Financial Officer (Age 56)
  • Scott N. Braunstein M.D., Chief Operating Officer (Age 53)
  • James B. Jones M.D., Senior Vice President, Chief Medical Officer (Age 52)
  • Kristen Marie Williams, Chief Administrative Officer, General Counsel, Secretary (Age 43)
  • Richard Scranton M.D., Chief Scientific Officer
  • Robert J. Weiland, Chief Commercial Officer (Age 57)
  • Mark Froimson, Director
  • Gary Pace Ph.D., Director (Age 69)
  • Laura A. Brege, Independent Director (Age 59)

Who owns Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.46%) and Bank of Montreal Can (0.07%). Company insiders that own Pacira Pharmaceuticals stock include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.

Who sold Pacira Pharmaceuticals stock? Who is selling Pacira Pharmaceuticals stock?

Pacira Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Schwab Charles Investment Management Inc.. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Scott Braunstein. View Insider Buying and Selling for Pacira Pharmaceuticals.

How do I buy Pacira Pharmaceuticals stock?

Shares of Pacira Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacira Pharmaceuticals' stock price today?

One share of Pacira Pharmaceuticals stock can currently be purchased for approximately $40.30.

How big of a company is Pacira Pharmaceuticals?

Pacira Pharmaceuticals has a market capitalization of $1.63 billion and generates $276.37 million in revenue each year. The company earns $-37,940,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Pacira Pharmaceuticals employs 503 workers across the globe.

How can I contact Pacira Pharmaceuticals?

Pacira Pharmaceuticals' mailing address is 5 Sylvan Way Ste 300, PARSIPPANY, NJ 07054-3813, United States. The company can be reached via phone at +1-973-2543560 or via email at [email protected]


MarketBeat Community Rating for Pacira Pharmaceuticals (PCRX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  541 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  832
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacira Pharmaceuticals (NASDAQ:PCRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.442.392.592.50
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.47$49.21$52.62$56.00
Price Target Upside: 16.53% upside12.23% upside59.20% upside13.82% upside

Pacira Pharmaceuticals (NASDAQ:PCRX) Consensus Price Target History

Price Target History for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ:PCRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018WedbushReiterated RatingBuyLowView Rating Details
1/4/2018HC WainwrightSet Price TargetBuy -> Buy$52.00 -> $55.00LowView Rating Details
1/4/2018JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
1/4/2018Canaccord GenuitySet Price TargetBuy -> Buy$42.00 -> $46.00MediumView Rating Details
1/4/2018Royal Bank of CanadaSet Price TargetBuy$54.00HighView Rating Details
1/2/2018Leerink SwannInitiated CoverageMkt Perform -> Market Perform$46.00LowView Rating Details
11/29/2017MizuhoDowngradeBuy -> Neutral$53.00 -> $44.00MediumView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetSell$27.00N/AView Rating Details
11/9/2017OppenheimerReiterated RatingHoldN/AView Rating Details
11/9/2017Jefferies GroupLower Price TargetBuy$52.00N/AView Rating Details
11/8/2017BMO Capital MarketsBoost Price TargetMarket Perform$38.00 -> $39.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$55.00N/AView Rating Details
10/19/2017Needham & Company LLCLower Price TargetBuy -> Buy$55.00 -> $52.00N/AView Rating Details
10/4/2017Bank of AmericaLower Price TargetBuy$46.00 -> $45.00LowView Rating Details
9/28/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$41.00MediumView Rating Details
9/7/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
8/2/2017CowenReiterated RatingHoldMediumView Rating Details
3/21/2017BarclaysReiterated RatingOverweight -> Overweight$54.00 -> $59.00HighView Rating Details
10/7/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00N/AView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings History and Estimates Chart

Earnings by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018$0.11N/AView Earnings Details
11/8/2017Q3 2017($0.04)$0.11$68.99 million$67.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.11)$73.37 million$70.90 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.23)($0.19)$70.30 million$69.30 millionViewListenView Earnings Details
3/1/2017Q416$0.01$0.09$73.08 million$72.90 millionViewListenView Earnings Details
11/2/2016Q316($0.02)$0.20$67.16 million$68.40 millionViewListenView Earnings Details
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.43)($0.42)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.49)($0.61)ViewN/AView Earnings Details
3/7/2013Q4 2012($0.41)($0.50)ViewN/AView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.43)($0.27)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.39)($0.47)ViewN/AView Earnings Details
3/27/2012Q4 2011($0.54)($0.58)ViewN/AView Earnings Details
10/31/2011Q3 2011($0.59)($0.55)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.58)($0.51)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.53)($0.98)ViewN/AView Earnings Details
3/31/2011Q4 2010($11.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pacira Pharmaceuticals (NASDAQ:PCRX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.85 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.60%
Insider Trades by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)
Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Pacira Pharmaceuticals (NASDAQ PCRX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018David M. StackCEOSell28,885$40.19$1,160,888.15View SEC Filing  
12/15/2017Lauren Bullaro RikerVPSell340$43.70$14,858.00View SEC Filing  
11/20/2017James B. JonesSVPSell850$41.11$34,943.50View SEC Filing  
11/17/2017Kristen Marie WilliamsCAOSell10,000$40.00$400,000.0023,455View SEC Filing  
11/15/2017David M StackCEOSell58,885$38.34$2,257,650.90159,164View SEC Filing  
11/10/2017Mark A KronenfeldDirectorBuy1,000$41.60$41,600.006,795View SEC Filing  
8/22/2017Paul J HastingsDirectorSell1,044$36.15$37,740.603,518View SEC Filing  
8/15/2017David M StackCEOSell28,885$36.37$1,050,547.45159,164View SEC Filing  
8/15/2017Kristen Marie WilliamsCAOSell3,461$36.75$127,191.7521,312View SEC Filing  
8/8/2017Mark FroimsonDirectorBuy100$37.13$3,713.00100View SEC Filing  
6/5/2017David M StackCEOSell4,311$43.32$186,752.5259,559View SEC Filing  
6/5/2017James S ScibettaPresidentSell1,966$43.32$85,167.1225,118View SEC Filing  
6/5/2017Kristen Marie WilliamsCAOSell1,877$43.32$81,311.6413,773View SEC Filing  
6/5/2017Lauren Bullaro RikerVPSell601$43.32$26,035.32View SEC Filing  
6/5/2017Scott BraunsteinSVPSell768$43.32$33,269.769,982View SEC Filing  
5/15/2017James S ScibettaPresidentSell20,000$51.20$1,024,000.0047,084View SEC Filing  
5/15/2017Kristen Marie WilliamsCAOSell21,041$50.86$1,070,145.2618,775View SEC Filing  
1/17/2017David M. StackCEOSell15,000$38.41$576,150.00View SEC Filing  
1/17/2017James S ScibettaPresidentSell20,000$38.53$770,600.0029,457View SEC Filing  
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.085,945View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.006,900View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.205,945View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.002,950View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.0025,285View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.002,000View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.001,500View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00285View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.001,000View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.002,300View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00176View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.0010,504View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.001,208View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.005,000View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.002,987View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.005,000View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacira Pharmaceuticals (NASDAQ PCRX) News Headlines

Source:
DateHeadline
$78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter$78.08 Million in Sales Expected for Pacira Pharmaceuticals, Inc. (PCRX) This Quarter
www.americanbankingnews.com - January 15 at 11:04 AM
Theravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head SurveyTheravance Biopharma (TBPH) and Pacira Pharmaceuticals (PCRX) Head to Head Survey
www.americanbankingnews.com - January 14 at 3:58 AM
Pacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 SharesPacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 28,885 Shares
www.americanbankingnews.com - January 12 at 6:26 PM
Pacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to HoldPacira Pharmaceuticals (PCRX) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - January 10 at 11:28 PM
WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical ProceduresWellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize Outcomes Across Surgical Procedures
finance.yahoo.com - January 9 at 10:16 AM
WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize ... - GlobeNewswire (press release)WellStar Health System and Pacira Pharmaceuticals Announce Partnership to Minimize Opioid Use and Standardize ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 10:32 AM
Pacira Pharmaceuticals (PCRX) Lowered to "Hold" at BidaskClubPacira Pharmaceuticals (PCRX) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - January 6 at 5:06 PM
Pacira Pharmaceuticals (PCRX) Receives Buy Rating from WedbushPacira Pharmaceuticals (PCRX) Receives Buy Rating from Wedbush
www.americanbankingnews.com - January 5 at 8:44 PM
Leerink Swann Comments on Pacira Pharmaceuticals, Inc.s FY2022 Earnings (PCRX)Leerink Swann Comments on Pacira Pharmaceuticals, Inc.'s FY2022 Earnings (PCRX)
www.americanbankingnews.com - January 5 at 8:08 PM
Pacira Pharma (PCRX) Announces Preliminary 2017 Revenues of $286.6M - StreetInsider.comPacira Pharma (PCRX) Announces Preliminary 2017 Revenues of $286.6M - StreetInsider.com
www.streetinsider.com - January 4 at 4:34 PM
Pacira Pharmaceuticals (PCRX) PT Set at $55.00 by HC WainwrightPacira Pharmaceuticals (PCRX) PT Set at $55.00 by HC Wainwright
www.americanbankingnews.com - January 4 at 3:38 PM
Pacira Pharmaceuticals (PCRX) Rating Reiterated by JPMorgan Chase & Co.Pacira Pharmaceuticals (PCRX) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - January 4 at 3:38 PM
Canaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $46.00 Price TargetCanaccord Genuity Analysts Give Pacira Pharmaceuticals (PCRX) a $46.00 Price Target
www.americanbankingnews.com - January 4 at 12:40 PM
Pacira Pharmaceuticals (PCRX) PT Set at $54.00 by Royal Bank of CanadaPacira Pharmaceuticals (PCRX) PT Set at $54.00 by Royal Bank of Canada
www.americanbankingnews.com - January 4 at 10:28 AM
Pacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 MillionPacira Pharmaceuticals Reports Preliminary 2017 Revenues of $286.6 Million
finance.yahoo.com - January 4 at 10:17 AM
Pacira Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)Pacira Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 3 at 4:37 PM
Pacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare ConferencePacira Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 9:36 AM
Pacira Pharmaceuticals (PCRX) Research Coverage Started at Leerink SwannPacira Pharmaceuticals (PCRX) Research Coverage Started at Leerink Swann
www.americanbankingnews.com - January 2 at 5:18 PM
Pacira Pharmaceuticals (PCRX) Stock Rating Reaffirmed by Canaccord GenuityPacira Pharmaceuticals (PCRX) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - December 29 at 5:04 PM
Pacira Pharmaceuticals (PCRX) Upgraded by BidaskClub to "Buy"Pacira Pharmaceuticals (PCRX) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - December 29 at 8:46 AM
Pacira Pharmaceuticals, Inc. (PCRX) Expected to Post Quarterly Sales of $77.89 MillionPacira Pharmaceuticals, Inc. (PCRX) Expected to Post Quarterly Sales of $77.89 Million
www.americanbankingnews.com - December 29 at 7:02 AM
Pacira Pharmaceuticals, Inc. (PCRX) Expected to Announce Earnings of $0.12 Per SharePacira Pharmaceuticals, Inc. (PCRX) Expected to Announce Earnings of $0.12 Per Share
www.americanbankingnews.com - December 27 at 7:28 PM
IBD Rating Upgrades: Pacira Pharmaceuticals Shows Improved Relative Price StrengthIBD Rating Upgrades: Pacira Pharmaceuticals Shows Improved Relative Price Strength
finance.yahoo.com - December 27 at 12:19 PM
ETFs with exposure to Pacira Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Pacira Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 4:45 PM
Shire (SHPG) versus Pacira Pharmaceuticals (PCRX) Critical ReviewShire (SHPG) versus Pacira Pharmaceuticals (PCRX) Critical Review
www.americanbankingnews.com - December 26 at 3:46 AM
Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Pacira Pharmaceuticals, Inc. :PCRX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 6:08 PM
Wedbush Weighs in on Pacira Pharmaceuticals, Inc.s FY2019 Earnings (PCRX)Wedbush Weighs in on Pacira Pharmaceuticals, Inc.'s FY2019 Earnings (PCRX)
www.americanbankingnews.com - December 25 at 3:02 PM
Pacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of "Hold" from BrokeragesPacira Pharmaceuticals, Inc. (PCRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 25 at 2:30 AM
Pacira Pharmaceuticals (PCRX) Rating Lowered to Hold at BidaskClubPacira Pharmaceuticals (PCRX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - December 24 at 6:50 AM
Pacira Pharmaceuticals (PCRX) "Buy" Rating Reaffirmed at WedbushPacira Pharmaceuticals' (PCRX) "Buy" Rating Reaffirmed at Wedbush
www.americanbankingnews.com - December 20 at 8:50 PM
Analyzing Pacira Pharmaceuticals (PCRX) and Marinus Pharmaceuticals (MRNS)Analyzing Pacira Pharmaceuticals (PCRX) and Marinus Pharmaceuticals (MRNS)
www.americanbankingnews.com - December 20 at 3:10 PM
Pacira Pharmaceuticals (PCRX) Now Covered by Analysts at J P Morgan Chase & CoPacira Pharmaceuticals (PCRX) Now Covered by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - December 18 at 10:32 PM
Insider Selling: Pacira Pharmaceuticals, Inc. (PCRX) VP Sells 340 Shares of StockInsider Selling: Pacira Pharmaceuticals, Inc. (PCRX) VP Sells 340 Shares of Stock
www.americanbankingnews.com - December 18 at 10:16 PM
Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to ... - GlobeNewswire (press release)Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to ... - GlobeNewswire (press release)
globenewswire.com - December 14 at 5:06 PM
Illinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical PatientsIllinois Surgical Quality Improvement Collaborative and Pacira Pharmaceuticals, Inc. Announce Collaboration to Minimize Opioid Exposure for Postsurgical Patients
finance.yahoo.com - December 14 at 10:30 AM
Stocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS RatingStocks Showing Improving Market Leadership: Pacira Pharmaceuticals Earns 81 RS Rating
finance.yahoo.com - December 13 at 10:44 AM
 Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) Will Announce Quarterly Sales of $77.59 Million
www.americanbankingnews.com - December 12 at 8:18 AM
Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?
finance.yahoo.com - December 11 at 11:03 AM
 Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share Brokerages Anticipate Pacira Pharmaceuticals, Inc. (PCRX) to Announce $0.12 Earnings Per Share
www.americanbankingnews.com - December 10 at 11:20 AM
Pacira Pharmaceuticals Sees RS Rating Climb To 75Pacira Pharmaceuticals Sees RS Rating Climb To 75
finance.yahoo.com - December 9 at 10:22 AM
Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer - MarketWatchPacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer - MarketWatch
www.marketwatch.com - December 8 at 10:21 AM
Pacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer - StreetInsider.comPacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer - StreetInsider.com
www.streetinsider.com - December 7 at 4:51 PM
Pacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific OfficerPacira Pharma (PCRX) Names Scott Braunstein as COO and Richard Scranton as Chief Scientific Officer
www.streetinsider.com - December 7 at 10:45 AM
Pacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officerPacira Pharmaceuticals names Scott Braunstein COO, Richard Scranton as chief scientific officer
finance.yahoo.com - December 7 at 10:45 AM
Notable Two Hundred Day Moving Average Cross - PCRXNotable Two Hundred Day Moving Average Cross - PCRX
www.nasdaq.com - December 6 at 4:36 PM
Contrasting Dr. Reddys Laboratories (RDY) and Pacira Pharmaceuticals (PCRX)Contrasting Dr. Reddy's Laboratories (RDY) and Pacira Pharmaceuticals (PCRX)
www.americanbankingnews.com - December 5 at 1:10 AM
Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc ...Cancer Treatment Centers of America® Teams with Pacira Pharmaceuticals, Inc ...
www.prnewswire.com - November 30 at 4:33 PM
Pacira Pharmaceuticals (PCRX) PT Set at $42.00 by Canaccord GenuityPacira Pharmaceuticals (PCRX) PT Set at $42.00 by Canaccord Genuity
www.americanbankingnews.com - November 30 at 12:00 PM
Pacira Pharmaceuticals, Inc. (PCRX) Given Average Rating of "Hold" by BrokeragesPacira Pharmaceuticals, Inc. (PCRX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 1:52 AM
Pacira Pharmaceuticals (PCRX) Stock Rating Lowered by MizuhoPacira Pharmaceuticals (PCRX) Stock Rating Lowered by Mizuho
www.americanbankingnews.com - November 29 at 8:54 PM

SEC Filings

Pacira Pharmaceuticals (NASDAQ:PCRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacira Pharmaceuticals (NASDAQ:PCRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacira Pharmaceuticals (NASDAQ PCRX) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.